Movatterモバイル変換


[0]ホーム

URL:


KR927002347A - (N-phthalimidoalkyl) piperidine - Google Patents

(N-phthalimidoalkyl) piperidine
Download PDF

Info

Publication number
KR927002347A
KR927002347AKR1019920700969AKR920700969AKR927002347AKR 927002347 AKR927002347 AKR 927002347AKR 1019920700969 AKR1019920700969 AKR 1019920700969AKR 920700969 AKR920700969 AKR 920700969AKR 927002347 AKR927002347 AKR 927002347A
Authority
KR
South Korea
Prior art keywords
compound
oxygen
composition
carbon atoms
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019920700969A
Other languages
Korean (ko)
Inventor
시가네크 엥겔베르트
윌리암 탐 생
소렌티노 라이트 앤
Original Assignee
레이몬드 지. 아너
더 두 퐁 머크 파마슈티칼 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레이몬드 지. 아너, 더 두 퐁 머크 파마슈티칼 캄파니filedCritical레이몬드 지. 아너
Publication of KR927002347ApublicationCriticalpatent/KR927002347A/en
Withdrawnlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

Translated fromKorean

내용 없음No content

Description

Translated fromKorean
(N-프탈아미도알킬) 피페리딘(N-phthalamidoalkyl) piperidine

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (88)

Translated fromKorean
일반식(Ⅰ)의 화합물, 또는 약제학적으로 허용되는 이의 염 또는 N-옥사이드.A compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof.상기식에서, a는 단일 또는 이중 결합인뎨, 단 a가 이중결합인 경우, R2(CH2)n은 C-4에 결합되며 R16은 적용되지 않고; n은 0 내지 4인데, 단(CH2)nR2가 피페리딘 환의 2-위치에 존재하는 경우, n은 2 내지 4이며; R1은 (CH2)mR3또는 (CH2)pAr(여기서, m 및 P는 각각 1 내지 4이다)이고;Wherein a is a single or double bond, provided that when a is a double bond, R2 (CH2 ) n is bonded to C-4 and R16 is not applied; n is 0 to 4, provided that when (CH2 ) nR2 is at the 2-position of the piperidine ring, n is 2 to 4; R1 is (CH2 ) mR3 or (CH2 ) pAr, wherein m and P are each 1 to 4;R2R2 is이며;Is;R3은 탄소수 3 내지 8의 사이클로알킬이고: R4는 H, 할로겐, NO2, NH2, 탄소수가 1 내지 3이고 할로겐수가 1 내지 7인 할로알킬, C1-C3알킬, NHCOR7, NHCO-페닐, OH, OR8및 Ar'로 이루어진 그룹 중에서 독립적으로 선택된 1 내지 4개의 치환체이며; R5및 R6는 독립적으로 H, 탄소수 1 내지 3의 알킬 또는 Ar"이거나, 함께 -CH=CH-CH=CH-를 형성하고; R7및 R8은 독립적으로 H 또는 탄소수 1 내지 3의 알킬이며; X는 산소; H2; H, OH; R9, OH; Ar"', OH; H, R9; 또는 H, OR9이고; Y는 CH2, CHR10, C(R10)2, 산소, CH2CH2, (CH2)3,R3 is cycloalkyl having 3 to 8 carbon atoms: R4 is H, halogen, NO2 , NH2 , haloalkyl having 1 to 3 carbon atoms and 1 to 7 halogen, C1 -C3 alkyl, NHCOR7 , 1 to 4 substituents independently selected from the group consisting of NHCO-phenyl, OH, OR8 and Ar '; R5 and R6 are independently H, alkyl of 1 to 3 carbon atoms or Ar ″, or together form —CH═CH—CH═CH—; R7 and R8 are independently H or of 1 to 3 carbon atoms X is oxygen; H2 ; H, OH; R9 , OH; Ar '' ′, OH; H, R9 ; Or H, OR9 ; Y is CH2 , CHR10 , C (R10 )2 , oxygen, CH2 CH2 , (CH2 )3 ,Ar, Ar', Ar" 및 Ar"'는 독립적으로, H, 할로겐, OH, 탄소수 1 내지 3의 알콕시, NR11R12, SH, S(O)tR13(여기서, t는 0 내지 2이다), 탄소수가 1 내지 3이고 할로겐수가 1 내지 7인 할로알킬, 탄소수 1 내지 3의 알킬, CO2H, 탄소수 2 내지 6의 카보알콕시, CN, NO2, SO2NH2, SO2H, CO2NR14R15또는 페닐로 이루어진 그룹 중에서 독립적으로 선택된 1 내지 5개의 치환체에 의해 각각 임의로 치환된, 페닐, 나프틸, 피리딜; 피리미딜, 퀴놀릴 또는 이소퀴놀릴이고, R9및 R10은 독립적으로 탄소수 1 내지 3의 이소퀴놀릴이고, R9및 R10은 독립적으로 탄소수 1 내지 3의 알킬이며; R11내지 R15는 독립적으로 H 또는 탄소수 1 내지 3의 알킬이고; R16은 H; OH; 탄소수 1 내지 6의 O-알킬; 탄소수 1 내지 8의 O-아실; 탄소수 1 내지 12의 알킬; F, Cl Br, I, 알킬, 페닐, 퍼플루오로알킬, 알콕시, 아릴옥시, 알킬티오, 아릴티오, 퍼플루오로알콕시, 퍼플루오로 알킬티오 또는 디알킬아미노(여기서, 알킬 및 알콕시의 탄소수 1 내지 12이고, 아릴의 탄소수 6 내지 12이다)로 이루어진 그룹 중에서 독립적으로 선택된 1 또는 2개의 치환체에 의해 임의로 치환된 페닐, 또는 1- 또는 2-나프틸; 또는 2- 및 3-피롤릴, 2- 및 3-푸릴, 2- 및 3-티에닐, 2,3, 및 4-피리딜, 2- 및 3-벤졸푸릴, 2- 및 3-인돌릴, 2- 및 3-벤조티에닐, 2,3, 및 4-퀴놀릴, 및 1,3, 및 4-이소퀴놀릴이며, 단, (1) n이 0이고, R2가 피페리딘 환의 C-4 위치에 결합되어 있는 경우,Ar, Ar ', Ar "and Ar"' are independently H, halogen, OH, alkoxy having 1 to 3 carbon atoms, NR11 R12 , SH, S (O) tR13 , wherein t is 0 to 2 ), Haloalkyl having 1 to 3 carbon atoms and 1 to 7 halogen, alkyl having 1 to 3 carbon atoms, CO2 H, carboalkoxy having 2 to 6 carbon atoms, CN, NO2 , SO2 NH2 , SO2 H, Phenyl, naphthyl, pyridyl, each optionally substituted with 1 to 5 substituents independently selected from the group consisting of CO2 NR14 R15 or phenyl; Pyrimidyl, quinolyl or isoquinolyl, R9 and R10 are independently isoquinolyl having 1 to 3 carbon atoms, and R9 and R10 are independently alkyl having 1 to 3 carbon atoms; R11 to R15 are independently H or alkyl having 1 to 3 carbon atoms; R16 is H; OH; O-alkyl of 1 to 6 carbon atoms; O-acyl having 1 to 8 carbon atoms; Alkyl having 1 to 12 carbon atoms; F, Cl Br, I, alkyl, phenyl, perfluoroalkyl, alkoxy, aryloxy, alkylthio, arylthio, perfluoroalkoxy, perfluoro alkylthio or dialkylamino, wherein alkyl and alkoxy have 1 carbon atom To 12, and aryl having 6 to 12 carbon atoms), phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of 1, or 1- or 2-naphthyl; Or 2- and 3-pyrrolyl, 2- and 3-furyl, 2- and 3-thienyl, 2,3, and 4-pyridyl, 2- and 3-benzolfuryl, 2- and 3-indolyl, 2- and 3-benzothienyl, 2,3, and 4-quinolyl, and 1,3, and 4-isoquinolyl, provided that (1) n is 0 and R2 is C in the piperidine ring When engaged in the -4 position,R2(여기서, X가 산호; H2;R2 is Wherein X is coral; H2 ;또는 H, OH인 경우, 2개의 R4치환체가 존재하며, 그중 하나는 H2NSO2이고 다른 하나는 할로겐 또는 CF3이다)일 수 없고, (2) R1이 (CH2)pAr이고 p가 1 이며 -(CH2)nR2(여기서, n은 1 내지 4이다)가 피페리딘 환의 C-4 위치에 결합되어 있는 경우, R2Or H, OH, there are two R4 substituents, one of which cannot be H2 NSO2 and the other is halogen or CF3 ), (2) R1 is (CH2 ) pAr and p When is 1 and-(CH2 ) n R2 , where n is 1 to 4, is bonded at the C-4 position of the piperidine ring, R2 is수 없으며; (3) R1이 (CH2)pAr (여기서, p는 1이다)이고;Can not; (3) R1 is (CH2 ) pAr where p is 1;R2이며;R2 Is;R4가 H, 알킬, CF3, 할로겐 또는 알콕시이고; (CH2)nR2(여기서, n은 0이다)이 피페리딘 환의 C-4 위치에 결합되어 있는 경우, X는 H2또는 산소일 수 없고; (4) R1이 (CH2)pAr (여기서, p는 0 보다 큰 수이다)이고, R2가 피페리딘 환의 C-3 또는 C-4 위치에 결합되어 있는R4 is H, alkyl, CF3 , halogen or alkoxy; When (CH2 ) nR2 (where n is 0) is bonded at the C-4 position of the piperidine ring, X may not be H2 or oxygen; (4) R1 is (CH2 ) pAr where p is a number greater than 0 and R2 is bonded to the C-3 or C-4 position of the piperidine ring(여기서, R4는 H, 할로겐, Where R4 is H, halogen,CF3, 알킬, 알콕시, NH2, 알킬아미노 및 디알킬 아미노이다)인 경우, X는 산소일 수 없으며; (5) (CH2)nR2가 피페리딘 환의 C-4 위치에 결합되어 있는 경우, R16는 H, OH, 알킬 또는 아릴이다.CF3 , alkyl, alkoxy, NH2 , alkylamino and dialkyl amino), X may not be oxygen; (5) When (CH2 ) nR2 is bonded at the C-4 position of the piperidine ring, R16 is H, OH, alkyl or aryl.제1항에 있어서, n이 1 내지 4인 화합물.The compound of claim 1, wherein n is 1-4.제1항에 있어서, R1이 (CH2)pAr인 화합물.The compound of claim 1, wherein R1 is (CH2 ) pAr.제1항에 있어서, R2The compound of claim 1, wherein R2 is또는(여기서,X, Y, R4, R5or Where X, Y, R4 , R5 andR6은 제1항에서 정의한 바와 같다)으로 이루어진 그룹 중에서 선택된 화합물.R6 is as defined in claim 1).제1항에 있어서, (CH2)nR2가 피페리딘 환의 C-4 위치에 결합되어 있는 화합물.The compound of claim 1, wherein (CH2 ) nR2 is bonded at the C-4 position of the piperidine ring.제1항에 있어서, X가 산소 또는 H2인 화합물.The compound of claim 1, wherein X is oxygen or H2 .제1항에 있어서, R4, R5및 R6이 모두 H인 화합물.The compound of claim 1, wherein R4 , R5 and R6 are all H. 3.제1항에 있어서, p가 1 또는 2인 화합물.The compound of claim 1, wherein p is 1 or 2.제1항에 있어서, Ar이 페닐인 화합물.The compound of claim 1, wherein Ar is phenyl.제1항에 있어서, Y가 (CH2)3또는 산소인 화합물.The compound of claim 1, wherein Y is (CH2 )3 or oxygen.제1항에 있어서, R1이 (CH2)pAr이고; (CH2)nR2가 피페리딘 환의 C-4 위치에 결합되어 있으며; n이 1 내지 4이고;The compound of claim 1, wherein R1 is (CH2 ) pAr; (CH2 ) nR2 is bonded at the C-4 position of the piperidine ring; n is 1 to 4;R2R2로 이루어진 그룹중에서 선택되며; X가 산소 또는 H2이고; R4, R5및 R6가 모두 H이며; p가 1 또는 2이고; Ar이 페닐이며, Y가 (CH2)3또는 산소인 화합물.Is selected from the group consisting of; X is oxygen or H2 ; R4 , R5 and R6 are all H; p is 1 or 2; Ar is phenyl and Y is (CH2 )3 or oxygen.제2항에 있어서, n이 1인 화합물.The compound of claim 2, wherein n is 1.제11항에 있어서, n이 1인 화합물.12. The compound of claim 11, wherein n is 1.제4항에 있어서,The method of claim 4, whereinR2인 화합물.R2 Phosphorus compounds.제11항에 있어서,The method of claim 11,R2인 화합물.R2 Phosphorus compounds.제6항에 있어서, X가 산소인 화합물.The compound of claim 6, wherein X is oxygen.제11항에 있어서, X가 산소인 화합물.The compound of claim 11, wherein X is oxygen.제14항에 있어서, X가 산소인 화합물.The compound of claim 14, wherein X is oxygen.제15항에 있어서, X가 산소인 화합물.The compound of claim 15, wherein X is oxygen.제8항에 있어서, p가 2인 화합물.The compound of claim 8, wherein p is 2. 10.제11항에 있어서, p가 2인 화합물.12. The compound of claim 11, wherein p is 2.제11항에 있어서, n이 1이고;12. The compound of claim 11 wherein n is 1;R2이며;R2 Is;X가 산소이고; R4가 H이며; p가 2이고; Ar이 페닐인 화합물.X is oxygen; R4 is H; p is 2; Ar is phenyl.제4항에 있어서,The method of claim 4, whereinR2인 화합물.R2 Phosphorus compounds.제11항에 있어서,The method of claim 11,R2인 화합물.R2 Phosphorus compounds.제23항에 있어서, X가 산소인 화합물.The compound of claim 23, wherein X is oxygen.제24항에 있어서, X가 산소인 화합물.The compound of claim 24, wherein X is oxygen.제10항에 있어서, Y가 (CH2)3인 화합물.The compound of claim 10, wherein Y is (CH2 )3 .제11항에 있어서, Y가 (CH2)3인 화합물.The compound of claim 11, wherein Y is (CH2 )3 .제23항에 있어서, Y가 (CH2)3인 화합물.The compound of claim 23, wherein Y is (CH2 )3 .제24항에 있어서, Y가 (CH2)3인 화합물.The compound of claim 24, wherein Y is (CH2 )3 .제11항에 있어서, n이 1이고;12. The compound of claim 11 wherein n is 1;R2이며;R2 Is;X가 산소이고; Y가 (CH2)3이며; R5및 R6가 H이고; p가 2이고; Ar이 페닐인 화합물.X is oxygen; Y is (CH2 )3 ; R5 and R6 are H; p is 2; Ar is phenyl.제10항에 있어서, Y가 산소인 화합물.The compound of claim 10, wherein Y is oxygen.제11항에 있어서, Y가 산소인 화합물.The compound of claim 11, wherein Y is oxygen.제23항에 있어서, Y가 산소인 화합물.The compound of claim 23, wherein Y is oxygen.제24항에 있어서, Y가 산소인 화합물.The compound of claim 24, wherein Y is oxygen.제11항에 있어서, n이 1이고;12. The compound of claim 11 wherein n is 1;R2이며;R2 Is;X 및 Y가 각각 산소이고; R5및 R6가 H이며; p가 2이고; Ar이 페닐인 화합물.X and Y are each oxygen; R5 and R6 are H; p is 2; Ar is phenyl.제4항에 있어서,The method of claim 4, whereinR2인 화합물.R2 Phosphorus compounds.제11항에 있어서,The method of claim 11,R2인 화합물.R2 Phosphorus compounds.제6항에 있어서, X가 H2인 화합물.The compound of claim 6, wherein X is H2 .제11항에 있어서, X가 H2인 화합물.The compound of claim 11, wherein X is H2 .제37항에 있어서, X가 H2인 화합물.The compound of claim 37, wherein X is H2 .제38항에 있어서, X가 H2인 화합물.The compound of claim 38, wherein X is H2 .제11항에 있어서, n이 1이고;12. The compound of claim 11 wherein n is 1;R2이며;R2 Is;X가 H2이고; R4가 H이며; p가 2이고; Ar이 페닐인 화합물.X is H2 ; R4 is H; p is 2; Ar is phenyl.정신병 또는 운동장애 치료학적 유효량의 일반식(Ⅰ)의 화합물, 또는 약제학적으로 허용되는 이의 염 또는 N-옥사이드, 및 약제학적으로 허용되는 담체를 포함함을 특징으로 하는 약제학적 조성물.A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof, and a pharmaceutically acceptable carrier.상기식에서, a는 단일 또는 이중 결합인데, 단 a가 이중결합인 경우, R2(CH2)n은 C-4에 결합되며 R16은 적용되지 않고; n은 0 내지 4인데, 단 (CH2)n R2가 피페리딘 환의 2-위치에 존재하는 경우, n은 2 내지 4이며; R1은 (CH2)mR3또는 (CH2)pAr (여기서, m 및 p는 각각 1 내지 4이다)이고;Wherein a is a single or double bond, provided that when a is a double bond, R2 (CH2 ) n is bonded to C-4 and R16 is not applied; n is 0 to 4, provided that when (CH2 ) n R2 is at the 2-position of the piperidine ring, n is 2 to 4; R1 is (CH2 ) mR3 or (CH2 ) pAr, wherein m and p are each 1 to 4;R2R2 is이며,Is,R3은 탄소수 3 내지 8의 사이클로알킬이고: R4는 H, 할로겐, NO2, NH2, 탄소수가 1 내지 3이고 할로겐수가 1 내지 7인 할로알킬, C1-C3알킬, NHCOR7, NHCO-페닐, OH, OR8및 Ar'로 이루어진 그룹 중에서 독립적으로 선택된 1 내지 4개의 치환체이며; R5및 R6는 독립적으로 H, 탄소수 1 내지 3의 알킬 또는 Ar"이거나, 함께 -CH=CH-CH=CH-를 형성하고; R7및 R8은 독립적으로 H 또는 탄소수 1 내지 3의 알킬이며; X는 산소;H2;H, OH;R9, OH;Ar"', OH;H, R9; 또는 H, OR9이고; Y는 CH2, CHR10, C(R10)2, 산소, CH2CH2, (CH2)3,R3 is cycloalkyl having 3 to 8 carbon atoms: R4 is H, halogen, NO2 , NH2 , haloalkyl having 1 to 3 carbon atoms and 1 to 7 halogen, C1 -C3 alkyl, NHCOR7 , 1 to 4 substituents independently selected from the group consisting of NHCO-phenyl, OH, OR8 and Ar '; R5 and R6 are independently H, alkyl of 1 to 3 carbon atoms or Ar ″, or together form —CH═CH—CH═CH—; R7 and R8 are independently H or of 1 to 3 carbon atoms X is oxygen; H2 ; H, OH; R9 , OH; Ar ″ ′, OH; H, R9 ; Or H, OR9 ; Y is CH2 , CHR10 , C (R10 )2 , oxygen, CH2 CH2 , (CH2 )3 ,Ar, Ar', Ar" 및 Ar"'는 독립적으로, H, 할로겐, OH, 탄소수 1 내지 3의 알콕시, NR11R12, SH, S(O)tR13(여기서, t는 0 내지 2이다), 탄소수가 1 내지 3이고 할로겐수가 1 내지 7인 할로알킬, 탄소수 1 내지 3의 알킬, CO2H, 탄소수 2 내지 6의 카보알콕시, CN, NO2, SO2NH2, SO2H, CO2NR14R15또는 페닐로 이루어진 그룹 중에서 독립적으로 선택된 1 내지 5개의 치환체에 의해 각각 임의로 치환된, 페닐, 나프틸, 피리딜; 피리미딜, 퀴놀릴 또는 이소퀴놀릴이고, R9및 R10은 독립적으로 탄소수 1 내지 3의 알킬이며; R11내지 R15는 독립적으로 H 또는 탄소수 1 내지 3의 알킬이고; R16은 H; OH; 탄소수 1 내지 6의 O-알킬; 탄소수 1 내지 8의 O-아실; 탄소수 1 내지 12의 알킬; F, Cl Br, I, 알킬, 페닐, 퍼플루오로알킬, 알콕시, 아릴옥시, 알킬티오, 아릴티오, 퍼플루오로알콕시, 퍼플루오로 알킬티오 또는 디알킬아미노(여기서, 알킬 및 알콕시의 탄소수 1 내지 12이고, 아릴의 탄소수 6 내지 12이다)로 이루어진 그룹 중에서 독립적으로 선택된 1 또는 2개의 치환체에 의해 임의로 치환된 페닐, 또는 1- 또는 2-나프틸; 또는 2- 및 3-피롤릴, 2- 및 3-푸릴, 2- 및 3-티에닐, 2,3, 및 4-피리딜, 2- 및 3-벤졸푸릴, 2- 및 3-인돌릴, 2- 및 3-벤조티에닐, 2,3, 및 4-퀴놀릴, 및 1,3, 및 4-이소퀴놀릴이며, 단, (1) R1이 (CH2)pAr (여기서, p는 1이다)이고;Ar, Ar ', Ar "and Ar"' are independently H, halogen, OH, alkoxy having 1 to 3 carbon atoms, NR11 R12 , SH, S (O) tR13 , wherein t is 0 to 2 ), Haloalkyl having 1 to 3 carbon atoms and 1 to 7 halogen, alkyl having 1 to 3 carbon atoms, CO2 H, carboalkoxy having 2 to 6 carbon atoms, CN, NO2 , SO2 NH2 , SO2 H, Phenyl, naphthyl, pyridyl, each optionally substituted with 1 to 5 substituents independently selected from the group consisting of CO2 NR14 R15 or phenyl; Pyrimidyl, quinolyl or isoquinolyl, R9 and R10 are independently alkyl having 1 to 3 carbon atoms; R11 to R15 are independently H or alkyl having 1 to 3 carbon atoms; R16 is H; OH; O-alkyl of 1 to 6 carbon atoms; O-acyl having 1 to 8 carbon atoms; Alkyl having 1 to 12 carbon atoms; F, Cl Br, I, alkyl, phenyl, perfluoroalkyl, alkoxy, aryloxy, alkylthio, arylthio, perfluoroalkoxy, perfluoro alkylthio or dialkylamino, wherein alkyl and alkoxy have 1 carbon atom To 12, and aryl having 6 to 12 carbon atoms), phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of 1, or 1- or 2-naphthyl; Or 2- and 3-pyrrolyl, 2- and 3-furyl, 2- and 3-thienyl, 2,3, and 4-pyridyl, 2- and 3-benzolfuryl, 2- and 3-indolyl, 2- and 3-benzothienyl, 2,3, and 4-quinolyl, and 1,3, and 4-isoquinolyl, provided that (1) R1 is (CH2 ) pAr where p is 1);R2이며;R2 Is;(CH2)nR2(여기서, n은 0이다)이 피페리딘 환의 C-4 위치에 결합되어 있는 경우, X는 H2일 수 없고; (2) (CH2)nR2가 피페리딘 환의 C-4 위치에 결합되어 있는 경우, R16는 H, OH, 알킬 또는 아릴이다.When (CH2 ) nR2 , where n is 0, is bonded at the C-4 position of the piperidine ring, X cannot be H2 ; (2) When (CH2 ) nR2 is bonded at the C-4 position of the piperidine ring, R16 is H, OH, alkyl or aryl.제44항에 있어서, n이 1 내지 4인 조성물.45. The composition of claim 44, wherein n is 1-4.제44항에 있어서, R1이 (CH2)pAr인 조성물.45. The composition of claim 44, wherein R1 is (CH2 ) pAr.제44항에 있어서,The method of claim 44,R2R2또는(여기서, X, Y, R4, R15or Where X, Y, R4 , R15 andR6는 제44항에서 정의된 바와 같다)으로 이루어진 그룹 중에서 선택된 조성물.R6 is as defined in claim 44).제44항에 있어서, (CH2)nR2이 피페리딘 환의 C-4 위치에 결합되어 있는 조성물.45. The composition of claim 44, wherein (CH2 ) nR2 is bonded at the C-4 position of the piperidine ring.제44항에 있어서, X가 산소 또는 H2인 조성물.45. The composition of claim 44, wherein X is oxygen or H2 .제44항에 있어서, R4, R5및 R6이 모두 H인 조성물.45. The composition of claim 44, wherein R4 , R5 and R6 are all H. 45.제44항에 있어서, p가 1 또는 2인 조성물.45. The composition of claim 44, wherein p is 1 or 2.제44항에 있어서, Ar이 페닐인 조성물.45. The composition of claim 44, wherein Ar is phenyl.제44항에 있어서, Y가 (CH2)3또는 산소인 조성물.45. The composition of claim 44, wherein Y is (CH2 )3 or oxygen.제44항에 있어서, R1이 (CH2)pAr이고; (CH2)nR2가 피페리딘 환의 C-4 위치에 결합되어 있으며, n이 1 내지 4이고;45. The compound of claim 44, wherein R1 is (CH2 ) pAr; (CH2 ) nR2 is bonded at the C-4 position of the piperidine ring, n is 1 to 4;R2R2또는으로 이루어진 그룹 중에서or Of groups선택되며; X가 산소 또는 H2이고; R4, R5및 R6가 모두 H이며; p가 1 또는 2이고; Ar이 페닐이며; Y가 (CH2)3또는 산소인 조성물.Selected; X is oxygen or H2 ; R4 , R5 and R6 are all H; p is 1 or 2; Ar is phenyl; Y is (CH2 )3 or oxygen.제45항에 있어서, n이 1인 조성물.46. The composition of claim 45, wherein n is one.제54항에 있어서, n이 1인 조성물.55. The composition of claim 54, wherein n is one.제47항에 있어서,The method of claim 47,R2인 조성물.R2 Phosphorus composition.제54항에 있어서,The method of claim 54,R2인 조성물.R2 Phosphorus composition.제49항에 있어서, X가 산소인 조성물.The composition of claim 49 wherein X is oxygen.제54항에 있어서, X가 산소인 조성물.55. The composition of claim 54, wherein X is oxygen.제57항에 있어서, X가 산소인 조성물.58. The composition of claim 57, wherein X is oxygen.제58항에 있어서, X가 산소인 조성물.59. The composition of claim 58, wherein X is oxygen.제51항에 있어서, p가 2인 조성물.The composition of claim 51 wherein p is 2.제54항에 있어서, p가 2인 조성물.55. The composition of claim 54, wherein p is 2.제54항에 있어서, n이 1이고;55. The compound of claim 54 wherein n is 1;R2이며;R2 Is;X가 산소이고; R4가 H이며; p가 2이고; Ar이 페닐인 조성물.X is oxygen; R4 is H; p is 2; Ar is phenyl.제47항에 있어서,The method of claim 47,R2인 조성물.R2 Phosphorus composition.제54항에 있어서,The method of claim 54,R2인 조성물.R2 Phosphorus composition.제66항에 있어서, X가 산소인 조성물.67. The composition of claim 66, wherein X is oxygen.제67항에 있어서, X가 산소인 조성물.The composition of claim 67 wherein X is oxygen.제53항에 있어서, Y가 (CH2)3인 조성물.The composition of claim 53, wherein Y is (CH2 )3 .제54항에 있어서, Y가 (CH2)3인 조성물.55. The composition of claim 54, wherein Y is (CH2 )3 .제66항에 있어서, Y가 (CH2)3인 조성물.67. The composition of claim 66, wherein Y is (CH2 )3 .제67항에 있어서, Y가 (CH2)3인 조성물.The composition of claim 67 wherein Y is (CH2 )3 .제54항에 있어서, n이 1이고;55. The compound of claim 54 wherein n is 1;R2이며;R2 Is;X가 산소이고; Y가 (CH2)3이며; R5및 R6이 H이고; p가 2이고; Ar이 페닐인 조성물.X is oxygen; Y is (CH2 )3 ; R5 and R6 are H; p is 2; Ar is phenyl.제53항에 있어서, Y가 산소인 조성물.The composition of claim 53 wherein Y is oxygen.제54항에 있어서, Y가 산소인 조성물.55. The composition of claim 54, wherein Y is oxygen.제66항에 있어서, Y가 산소인 조성물.67. The composition of claim 66, wherein Y is oxygen.제67항에 있어서, Y가 산소인 조성물.68. The composition of claim 67, wherein Y is oxygen.제54항에 있어서, n이 1이고;55. The compound of claim 54 wherein n is 1;R2이며;R2 Is;X 및 Y가 각각 산소이고; R5및 R6가 H이고; p가 2이고; Ar이 페닐인 조성물.X and Y are each oxygen; R5 and R6 are H; p is 2; Ar is phenyl.제47항에 있어서,The method of claim 47,R2인 조성물.R2 Phosphorus composition.제54항에 있어서,The method of claim 54,R2인 조성물.R2 Phosphorus composition.제49항에 있어서, X가 H2인 조성물.The composition of claim 49 wherein X is H2 .제54항에 있어서, X가 H2인 조성물.55. The composition of claim 54, wherein X is H2 .제80항에 있어서, X가 H2인 조성물.81. The composition of claim 80, wherein X is H2 .제81항에 있어서, X가 H2인 조성물.82. The composition of claim 81, wherein X is H2 .제54항에 있어서, n이 1이고;55. The compound of claim 54 wherein n is 1;R2이며;R2 Is;X가 H2이고 R4가 H이며; p가 2이고; Ar이 페닐인 조성물.X is H2 and R4 is H; p is 2; Ar is phenyl.제44항 내지 제86항중 어느 한 항에 따른 조성물의 유효량을 포유동물의 정신병 또는 운동장애를 치료하는 방법.89. A method of treating a psychotic or motor disorder in a mammal in an effective amount of the composition according to any one of claims 44 to 86.(a)일반식(a) general formula(여기서, n은 Where n is0 내지 4의 수이다)의 피리디닐알킬아민을, 구조식Pyridinylalkylamine of 0 to 4)무수물과 같이, N-이 산소로 대체된 R2에 상응하는 무수물과 As with anhydrides, anhydrides corresponding to R2 with N- replaced by oxygen and반응시켜 일반식(여기서, n 및React to general formula Where n andR2는 제1항에서 정의한 바와 같으며, X는 산소이다)의 이미드를 수득하고; (b) 단계 (a)에서 수득한 이미다를 약 0 내지 200℃의 온도하에 적합한 용매중에서 일반식 R1Z(여기서, Z는 Cl, Br, I 또는 활성화된 에스테르 그룹이다)의 알킬화제와 반응시켜R2 is as defined in claim 1, wherein X is oxygen; (b) reacting the imida obtained in step (a) with an alkylating agent of the general formula R1 Z, wherein Z is Cl, Br, I or an activated ester group, in a suitable solvent at a temperature of about 0 to 200 ° C.일반식의 4급 피리디늄 염을General formula Quaternary pyridinium salt수득하고; (c) 단계 (b)에서 수득한 Z-염을, 임의로 적합한 산의 존재하에, 적합한 용매중에서 촉매적으로 수소화에 의해 환원시킴을 특징으로 하여, 제1항에 따른 일반식(Ⅰ)의 화합물을 제조하는 방법.To obtain; (c) the compound of formula (I) according to claim 1, characterized in that the Z-salt obtained in step (b) is catalytically reduced by hydrogenation in a suitable solvent, optionally in the presence of a suitable acid. How to prepare.상기식에서, a, R1, R2, R16및 n은 제1 항에서 정의한 바와 같다.Wherein a, R1 , R2 , R16 and n are as defined in claim 1.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920700969A1989-10-271990-10-29 (N-phthalimidoalkyl) piperidineWithdrawnKR927002347A (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US42809789A1989-10-271989-10-27
US7/4280971989-10-27
PCT/US1990/006102WO1991006297A1 (en)1989-10-271990-10-29(n-phthalimidoalkyl) piperidines

Publications (1)

Publication NumberPublication Date
KR927002347Atrue KR927002347A (en)1992-09-03

Family

ID=23697544

Family Applications (1)

Application NumberTitlePriority DateFiling Date
KR1019920700969AWithdrawnKR927002347A (en)1989-10-271990-10-29 (N-phthalimidoalkyl) piperidine

Country Status (5)

CountryLink
EP (1)EP0497843A4 (en)
KR (1)KR927002347A (en)
CA (1)CA2069318A1 (en)
WO (1)WO1991006297A1 (en)
ZA (1)ZA908641B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5356906A (en)*1989-10-271994-10-18The Du Pont Merck Pharmaceutical Company(N-phthalimidoalkyl) piperidines useful as treatments for psychosis
JP2807577B2 (en)*1990-06-151998-10-08エーザイ株式会社 Cyclic amide derivative
US5180729A (en)*1991-02-221993-01-19Du Pont Merck Pharmaceutical CompanyUse of sigma receptor antagonists for treatment of cocaine abuse
US5162341A (en)*1991-02-221992-11-10Du Pont Merck Pharmaceutical CompanyUse of sigma receptor antagonists for treatment of amphetamine abuse
WO1993022309A1 (en)*1992-04-231993-11-11Merrell Dow Pharmaceuticals Inc.4-imidomethyl-1-[2'phenyl-2'oxoethyl-] piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
FR2713639B1 (en)*1993-12-091996-08-30Irj New derivatives of 2-arylalkenyl-azacycloalkanes ligands to sigma receptors, their preparation process and their use in therapy.
GB9416571D0 (en)*1994-08-161994-10-12Battelle Memorial InstituteNovel alkylamino derivatives as sigma 2 selective ligands
ZA9610736B (en)*1995-12-221997-06-27Warner Lambert Co2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en)*1995-12-221997-06-24Warner Lambert Co4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en)1995-12-221997-06-24Warner Lambert CoSubtype selective nmda receptor ligands and the use thereof
ZA9610741B (en)1995-12-221997-06-24Warner Lambert Co4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
WO1999021539A1 (en)*1997-10-241999-05-06Warner-Lambert CompanyMethod for treating disease-related or drug-induced dyskinesias
ES2291293T3 (en)*2000-02-292008-03-01Mitsubishi Pharma Corporation NEW DERIVATIVES AMIDA CICLICOS.
US20040077605A1 (en)2001-06-202004-04-22Salvati Mark E.Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en)*2000-09-192007-11-28Bristol-Myers Squibb CompanyFused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002046156A2 (en)*2000-12-062002-06-13Sepracor, Inc.4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands
TWI263640B (en)*2001-12-192006-10-11Bristol Myers Squibb CoFused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2003053358A2 (en)2001-12-192003-07-03Bristol-Myers Squibb CompanyFused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
US7985756B2 (en)2005-10-212011-07-26Braincells Inc.Modulation of neurogenesis by PDE inhibition
JP2009513672A (en)2005-10-312009-04-02ブレインセルス,インコーポレイティド GABA receptor-mediated regulation of neurogenesis
US20100216734A1 (en)2006-03-082010-08-26Braincells, Inc.Modulation of neurogenesis by nootropic agents
JP2009536669A (en)2006-05-092009-10-15ブレインセルス,インコーポレイティド Neurogenesis by angiotensin regulation
US20100184806A1 (en)2006-09-192010-07-22Braincells, Inc.Modulation of neurogenesis by ppar agents
US20100216805A1 (en)2009-02-252010-08-26Braincells, Inc.Modulation of neurogenesis using d-cycloserine combinations
RS64819B1 (en)*2010-07-202023-12-29Minerva Neurosciences IncMethods of use of cyclic amide derivatives to treat schizophrenia and symptoms thereof
BR112013001302A2 (en)*2010-07-202017-07-04Cyrenaic Pharmaceuticals Inc methods of using cyclic amide derivatives to treat sigma receptor mediated disorders
MX385586B (en)2014-12-022025-03-18Minerva Neurosciences Inc COMPOSITIONS COMPRISING 2-((1-(2(4-FLUOROPHENYL)-2-OXOETHYL) PIPERIDIN-4-YL)METHYL)ISOINDOLIN-1-ONE FOR TREATING SCHIZOPHRENIA.
IL271606B2 (en)2017-06-212024-05-01Minerva Neurosciences Inc Stomach-resistant controlled-release oral dosage forms
US11083723B2 (en)2018-08-212021-08-10Minerva Neurosciences, Inc.Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
US11919860B1 (en)2023-10-062024-03-05King Faisal University1-2(-(substituted phenyl)-2-oxoethyl)-4-(isopropoxycarbonyl)pyridin-1-ium bromides as anti-tubercular agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB1425578A (en)*1972-10-211976-02-18Wyeth John & Brother LtdPiperidine derivatives
SE7907121L (en)*1979-08-271981-02-28Astra Laekemedel Ab FTALIMIDINDERIVAT
US4495194A (en)*1982-11-121985-01-22Mead Johnson & CompanyAntihypertensive isoindole derivatives
NZ216720A (en)*1985-07-081990-09-26Bristol Myers CoDiazinylpiperidine derivatives and pharmaceutical compositions
DE3717561A1 (en)*1987-05-251988-12-08Thomae Gmbh Dr K INDOL, ISOCHINOLINE AND BENZAZEPINE DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
DK623586A (en)*1985-12-271987-06-28Eisai Co Ltd PIPERIDE INGREDIENTS OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS
AU593194B2 (en)*1986-09-261990-02-01Sumitomo Pharmaceuticals Company, LimitedImide derivatives ,and their production and use
FI95572C (en)*1987-06-221996-02-26Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt

Also Published As

Publication numberPublication date
EP0497843A1 (en)1992-08-12
CA2069318A1 (en)1991-04-28
WO1991006297A1 (en)1991-05-16
EP0497843A4 (en)1992-09-23
ZA908641B (en)1992-06-24

Similar Documents

PublicationPublication DateTitle
KR927002347A (en) (N-phthalimidoalkyl) piperidine
KR870009996A (en) 3,3-disubstituted indolin and preparation method thereof
EP0264883A3 (en)Substituted pyridine derivatives
EP0945439A4 (en) NEW AMINOPYRAZOLE DERIVATIVES
KR840000533A (en) Preparation of Compound
GB1369401A (en)Process for the manufacture of 2-amino-1,4-dihydropyridines and their use as coronary agents
KR950011420A (en) Triazine Derivatives, Methods of Making and Uses thereof
GB1032889A (en)Picolinic acid derivatives and process for their preparation
EP0206616A3 (en)Quinolones having antihypertensive activity
DE68904558D1 (en) METHOD FOR PRODUCING BIDENTAL LIGANDS.
ATE113035T1 (en) 1,4-DIHYDROPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GB1389504A (en)2-amino-1,4-dihydropyridines their production and their medicinal use
KR840006482A (en) Method for preparing [3,4-b] pyridine derivative with dihydropyrazolo
KR940007020A (en) Pyreridine derivatives, their preparation and their use for treatment
DE3375917D1 (en)Thiomethylpyridine derivatives, process for their preparation and medicaments containing them
SE8800171L (en) NEW 5-OXY DERIVATIVES OF TETRAHYDROFURAN
HUT36819A (en)Process for preparing new flavene and thioflavene derivatives further pharmaceutical compositions containing thereof
KR910011839A (en) Imidazolidine Derivatives, Methods for Making the Same, and Insecticides Containing the Same
ATE34739T1 (en) NEW 2-PYRIDINE THIOL DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
ES8706637A1 (en) A PROCEDURE FOR PREPARING PIRIDINE DERIVATIVES
ES520868A0 (en) A PROCEDURE FOR PREPARING SUBSTITUTED GUANIDINO-PHENYLAMIDINES.
GB1380095A (en)Carboxamidobenzoic acids as hypolipemic agents
DE59711437D1 (en) Process for the preparation of arylamides of heteroaromatic carboxylic acids
IE42766L (en)Pharmaceutical preparations
ES383467A1 (en)Procedure for the preparation of pirrol derivatives. (Machine-translation by Google Translate, not legally binding)

Legal Events

DateCodeTitleDescription
PA0109Patent application

Patent event code:PA01091R01D

Comment text:Patent Application

Patent event date:19920427

PG1501Laying open of application
PC1203Withdrawal of no request for examination
WITNApplication deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid

[8]ページ先頭

©2009-2025 Movatter.jp